BioMedPartners
BioMedPartners is one of the leading European venture capital firms.
Business Model:
Revenue: $12.6M
Employees: 2-10
Rankings
Industries / Tags:
Detailed BioMedPartners Information
Geographic Data
Address: Elisabethenstr. 23
City: Basel
State: basel-country
Zip: 4051
Country: CH
Financial Info
Stage:
Raised Last:
$0
Raised Total:$75M
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 9/2008 | Lumavita | Series A | 16.2M |
| 11/2009 | Activaero | Series A | 15.8M |
| 5/2012 | Spinelab | Series C | 4.8M |
| 6/2021 | Alentis Therapeutics | Series B | 66.8M |
| 11/2010 | Delenex Therapeutics | Series A | 14M |
| 11/2004 | Symetis | Series A | 9.6M |
| 9/2014 | Affimed | Series E | 0 |
| 2/2011 | Activaero | Series A | 0 |
| 5/2016 | Aleva Neurotherapeutics | Series C | 18M |
| 12/2010 | SuppreMol | Series C | 20.4M |
| 5/2011 | Delenex Therapeutics | Series A | 19.3M |
| 8/2011 | Aleva Neurotherapeutics | Series A | 13.7M |
| 6/2020 | TOLREMO therapeutics | Series A | 5M |
| 4/2016 | Anergis | Series C | 5.2M |
| 12/2009 | Evolva | Post-IPO Equity | 27.5M |
| 12/2019 | ImmunOs Therapeutics | Series A | 0 |
| 6/2018 | Tricares | Series B | 25.7M |
| 4/2010 | Affimed | Series C | 0 |
| 11/2003 | Thommen Medical | Series C | 0 |
| 3/2011 | Anergis | Series A | 20M |
| 5/2013 | SuppreMol | Series D | 12.3M |
| 10/2009 | Evolva | Series B | 27.8M |
| 3/2022 | Scenic Biotech | Series A | 0 |
| 12/2014 | AYOXXA | Series B | 2.9M |
| 7/2021 | Topas Therapeutics | Series B | 0 |
| 11/2003 | Roche Glycart | Series A | 13.6M |
| 12/2019 | Aleva Neurotherapeutics | Series E | 8.1M |
| 12/2016 | Hookipa Pharma | Series B | 10.7M |
| 11/2018 | Precirix | Series A | 41.9M |
| 10/2006 | Santhera Pharmaceuticals | Series C | 0 |
| 9/2018 | TOLREMO therapeutics | Series A | 9.3M |
| 12/2007 | Vivendy Therapeutics | Series A | 15.4M |
| 11/2014 | Humedics | Series C | 7.8M |
| 10/2013 | Middle Peak Medical | Series A | 0 |
| 12/2014 | Anergis | Series B | 14.9M |
| 1/2018 | Miracor Medical | Series D | 0 |
| 10/2016 | Miracor Medical | Series C | 0 |
| 1/2015 | Miracor Medical | Series B | 5.3M |
| 3/2007 | Okairos | Series A | 9.6M |
| 10/2015 | Sequana Medical | Series C | 0 |
| 4/2014 | Sequana Medical | Series C | 26.1M |
| 2/2006 | EyeSense AG | Series A | 0 |
| 11/2014 | Curetis | Series B | 0 |
| 3/2014 | Inotrem | Series A | 25.1M |
| 9/2005 | Bioheart | Venture Round | 0 |
| 9/2005 | Spinal Cord Therapeutics GmbH | Series A | 15.5M |
| 10/2012 | Affimed | Series D | 20.1M |
| 8/2005 | Dolthera GmbH | Series B | 18M |
| 4/2007 | Affimed | Series B | 32M |
| 9/2022 | Tricares | Series C | 0 |
| 12/2009 | Curetis | Series A | 27.9M |
| 10/2007 | idiag | Venture Round | 3.8M |
| 3/2011 | Sequana Medical | Series B | 25.5M |
| 1/2015 | Genkyotex | Post-IPO Equity | 0 |
| 2/2014 | Anergis | Series A | 8.9M |
| 8/2009 | Spinelab | Series B | 10.2M |
| 4/2007 | Spinelab | Series A | 3.3M |
| 11/2013 | Hookipa Pharma | Series B | 27M |
| 8/2006 | ESBATech | Series B | 41M |
| 8/2008 | ESBATech | Series B | 22M |
| 12/2017 | Hookipa Pharma | Series C | 0 |
| 10/2020 | Topas Therapeutics | Series B | 0 |
| 5/2017 | Cardior Pharmaceuticals | Series A | 16.3M |
| 12/2020 | Noema Pharma | Series A | 60M |
| 3/2022 | Precirix | Series B | 0 |
| 11/2013 | Delenex Therapeutics | Series A | 8M |
| 10/2014 | ImevaX | Series A | 0 |
| 1/2011 | VAXIMM | Venture Round | 8M |
| 8/2021 | Cardior Pharmaceuticals | Series B | 0 |
| 5/2022 | Tubulis | Series B | 0 |
| 2/2020 | Azafaros | Series A | 27.5M |
| 3/2004 | 4-Antibody AG | Seed Round | 2.1M |
| 4/2019 | Alentis Therapeutics | Series A | 12.3M |
| 4/2012 | Aleva Neurotherapeutics | Series B | 4.4M |
| 7/2008 | SuppreMol | Series B | 25M |
| 6/2022 | ImmunOs Therapeutics | Series B | 0 |
| 7/2020 | Tubulis | Series A | 12.3M |
| 3/2004 | CareX SA | Series B | 32M |
| 9/2017 | Amal Therapeutics | Series B | 9.5M |
| 11/2018 | Amal Therapeutics | Series B | 32.6M |
| 6/2022 | ImmunOs Therapeutics | Series B | 0 |
| 5/2022 | Tubulis | Series B | 0 |
| 3/2022 | Precirix | Series B | 0 |
| 3/2022 | Scenic Biotech | Series A | 0 |
| 8/2021 | Cardior Pharmaceuticals | Series B | 0 |
| 7/2021 | Topas Therapeutics | Series B | 0 |
| 6/2021 | Alentis Therapeutics | Series B | 0 |
| 12/2020 | Noema Pharma | Series A | 0 |
| 10/2020 | Topas Therapeutics | Series B | 0 |
| 7/2020 | Tubulis | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
